Application of shRNA-containing herpes simplex virus type 1 (HSV-1)-based gene therapy for HSV-2-induced genital herpes

被引：3

作者：

Liu, Zhihong ^{[1
,2
]}

Xiang, Yang ^{[3
]}

Wei, Zhun ^{[2
,4
]}

Yu, Bo ^{[2
,4
,5
,6
]}

Shao, Yong ^{[2
,4
,5
,6
]}

Zhang, Jie ^{[2
,4
,5
,6
]}

Yang, Hong ^{[2
,4
,5
,7
]}

Li, Manmei ^{[8
]}

Guan, Ming ^{[9
]}

Wan, Jun ^{[2
,10
]}

Zhang, Wei ^{[2
,4
,5
]}

机构：

[1] Peking Univ, Shenzhen Hosp, Dept Obstet & Gynecol, Shenzhen 518036, Guangdong, Peoples R China

[2] Shenzhen PKU HKUST Med Ctr, Biomed Res Inst, Shenzhen 518036, Guangdong, Peoples R China

[3] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China

[4] Shenzhen PKU HKUST Med Ctr, Shenzhen Key Lab Translat Med Dermatol, Shenzhen 518036, Guangdong, Peoples R China

[5] Peking Univ, Shenzhen Hosp, Shenzhen Key Discipline Dermatol, Shenzhen 518036, Guangdong, Peoples R China

[6] Peking Univ, Shenzhen Hosp, Dept Dermatol, Shenzhen 518036, Guangdong, Peoples R China

[7] Peking Univ, Shenzhen Hosp, Dept Clin Lab, Shenzhen 518036, Guangdong, Peoples R China

[8] Ji Nan Univ, Coll Pharm, JNU HKUST Joint Lab, Jinan, Guangdong, Peoples R China

[9] Fudan Univ, Huashan Hosp, Cent Lab, Dept Lab Med, Shanghai 200040, Peoples R China

[10] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China

来源：

JOURNAL OF VIROLOGICAL METHODS | 2013年 / 193卷 / 02期

关键词：

Herpes simplex virus type 1 (HSV-1) vector; Herpes simplex virus type 2 (HSV-2); Genital herpes; IMMUNOGENICITY; GLYCOPROTEINS; PROTECTION; INFECTION; IMMUNITY; NEURONS; HSV-2; MODEL; MICE;

D O I：

10.1016/j.jviromet.2013.06.037

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

HSV-1-based vectors have been widely used to achieve targeted delivery of genes into the nervous system. In the current study, we aim to use shRNA-containing HSV-1-based gene delivery system for the therapy of HSV-2 infection. Guinea pigs were infected intravaginally with HSV-2 and scored daily for 100 days for the severity of vaginal disease. HSV-2 shRNA-containing HSV-1 was applied intravaginally daily between 8 and 14 days after HSV-2 challenge. Delivery of HSV-2 shRNA-containing HSV-1 had no effect on the onset of disease and acute virus shedding in animals, but resulted in a significant reduction in both the cumulative recurrent lesion days and the number of days with recurrent disease. Around half of the animals in the HSV-2 shRNA group did not develop recurrent disease 100 days post HSV-2 infection. In conclusion, HSV-2 shRNA-containing HSV-1 particles are effective in reducing the recurrence of genital herpes caused by HSV-2. (C) 2013 Elsevier B.V. All rights reserved.

引用

页码：353 / 358

页数：6

共 24 条

[1] Development of a Glycoprotein D-Expressing Dominant-Negative and Replication-Defective Herpes Simplex Virus 2 (HSV-2) Recombinant Viral Vaccine against HSV-2 Infection in Mice [J].

Akhrameyeva, Natalie V. ;

Zhang, Pengwei ;

Sugiyama, Nao ;

Behar, Samuel M. ;

Yao, Feng .

JOURNAL OF VIROLOGY, 2011, 85 (10) :5036-5047

[2] Disruption of the UL41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes [J].

Dudek, Timothy ;

Mathews, Lydia C. ;

Knipe, David M. .

VIROLOGY, 2008, 372 (01) :165-175

[3]

EPSTEIN AL, 1995, RESTOR NEUROL NEUROS, V8, P41, DOI 10.3233/RNN-1995-81210

[4] Herpes simplex virus type 2 in the United States, 1976 TO 1994 [J].

Fleming, DT ;

McQuillan, GM ;

Johnson, RE ;

Nahmias, AJ ;

Aral, SO ;

Lee, FK ;

StLouis, ME .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (16) :1105-1111

[5] Herpes simplex virus type-1 latency inhibits dendritic growth in sympathetic neurons [J].

Hamza, Mohamed A. ;

Higgins, Dennis M. ;

Ruyechan, William T. .

NEUROBIOLOGY OF DISEASE, 2006, 24 (02) :367-373

[6] HSV-1 amplicon viral vector-mediated gene transfer to human bone marrow-derived mesenchymal stem cells [J].

Ho, I. A. W. ;

Chan, K. Y. W. ;

Miao, L. ;

Shim, W. S. N. ;

Guo, C. M. ;

Cheang, P. ;

Hui, K. M. ;

Lam, P. Y. P. .

CANCER GENE THERAPY, 2008, 15 (09) :553-562

[7] Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs [J].

Hoshino, Y ;

Dalai, SK ;

Wang, K ;

Pesnicak, L ;

Lau, TY ;

Knipe, DM ;

Cohen, JI ;

Straus, SE .

JOURNAL OF VIROLOGY, 2005, 79 (01) :410-418

[8]

Kimberlin David W, 2005, Semin Pediatr Infect Dis, V16, P271, DOI 10.1053/j.spid.2005.06.007

[9] Recent progress in herpes simplex virus immunobiology and vaccine research [J].

Koelle, DM ;

Corey, L .

CLINICAL MICROBIOLOGY REVIEWS, 2003, 16 (01) :96-+

[10] Immunization with combined HSV-2 glycoproteins B2:D2 gene DNAs: Protection against lethal intravaginal challenges in mice [J].

Hoan Lee H. ;

Chul Cha S. ;

June Jang D. ;

Keun Lee J. ;

Wan Choo D. ;

Sik Kim Y. ;

Sun Uh H. ;

Young Kim S. .

Virus Genes, 2002, 25 (2) :179-188

← 1 2 3 →